Cantor Fitzgerald Reiterates Overweight on Sanara MedTech, Maintains $44 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Ross Osborn has reiterated an Overweight rating on Sanara MedTech (NASDAQ:SMTI) and maintained a $44 price target.
May 15, 2024 | 12:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Ross Osborn has reiterated an Overweight rating on Sanara MedTech (NASDAQ:SMTI) and maintained a $44 price target.
The reiteration of an Overweight rating and the maintenance of a $44 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100